Affiliation:
1. Institute of Neuroradiology University Hospital Erlangen, Friedrich Alexander University Erlangen‐Nürnberg Erlangen Germany
2. Department of Neurosurgery University Hospital Erlangen, Friedrich Alexander University Erlangen‐Nürnberg Erlangen Germany
3. High‐field Magnetic Resonance Center Max Planck Institute for Biological Cybernetics Tübingen Germany
4. Department Artificial Intelligence in Biomedical Engineering Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany
Abstract
AbstractChemical exchange saturation transfer (CEST) is a magnetic resonance (MR) imaging method providing molecular image contrasts based on indirect detection of low concentrated solutes. Previous CEST studies focused predominantly on the imaging of single CEST exchange regimes (e.g., slow, intermediate or fast exchanging groups). In this work, we aim to establish a so‐called comprehensive CEST protocol for 7 T, covering the different exchange regimes by three saturation B1 amplitude regimes: low, intermediate and high. We used the results of previous publications and our own simulations in pulseq‐CEST to produce a 7 T CEST protocol that has sensitivity to these three B1 regimes. With postprocessing optimization (simultaneous mapping of water shift and B1, B0‐fitting, multiple interleaved mode saturation B1 correction, neural network employment (deepCEST) and analytical input feature reduction), we are able to shorten our initially 40 min protocol to 15 min and generate six CEST contrast maps simultaneously. With this protocol, we measured four healthy subjects and one patient with a brain tumor. We established a comprehensive CEST protocol for clinical 7 T MRI, covering three different B1 amplitude regimes. We were able to reduce the acquisition time significantly by more than 50%, while still maintaining decent image quality and contrast in healthy subjects and one patient with a tumor. Our protocol paves the way to perform comprehensive CEST studies in clinical scan times for hypothesis generation regarding molecular properties of certain pathologies, for example, ischemic stroke or high‐grade brain tumours.
Funder
Deutsche Forschungsgemeinschaft
Max-Planck-Gesellschaft